FOR IMMEDIATE RELEASE
Amalgam Rx Announces Addition of Digital All-Stars to Leadership Team. Digital Health Company Appoints New President and Board Members.
WILMINGTON, DE — December 16, 2020 —Amalgam Rx, Inc., a leading Digital Therapeutics and Patient Support company, is announcing the hiring of a new president, Chris Bergstrom, former partner and head of digital therapeutics at Boston Consulting Group, and the appointment of Sonny Vu, serial entrepreneur, chief executive officer of AREVO, and former founder of Misfit to its Board of Directors. Vu will be joining Ryan Sysko and Jeff Courtney on the Board of Directors.
“Amalgam Rx is an experienced operator, not only building great products but launching them on a global scale. It is an opportune time for the addition of these accomplished voices to contribute to our growth as we reimagine patient care,” said Ryan Sysko, chief executive officer and founder of Amalgam Rx.
“I’m honored to join this talented team as Digital Health hits a universal inflection point. Amalgam Rx brings the best end-to-end experience to take our partners from concept to multinational commercialization. Amalgam’s modular platform empowers leading life sciences companies to support patients living with any disease, in any regulated environment,” said Chris Bergstrom, newly appointed president of Amalgam Rx.
About Chris Bergstrom
Chris Bergstrom has been at the forefront of digital health for more than a decade, recently serving as partner and head of digital therapy at Boston Consulting Group (BCG) where he helped the world’s leading life sciences companies design their digital health strategies. Prior to BCG, Bergstrom was chief commercial officer at WellDoc where he launched the world’s first digital therapy. As a recognized thought leader in the field, Bergstrom is a frequent speaker, championing the use of digital to decentralize healthcare and disrupt business models, and has served as advisor to many government and medical institutions. He also held executive roles at Roche, Becton Dickinson, and P&G. “Chris has been a pioneer in the digital therapeutics space for over a decade and we’re thrilled that he’s reuniting with the Amalgam Rx management team to continue to evolve the industry. He’s a global thought leader on utilizing technology to transform healthcare outcomes,” said Ryan Sysko, chief executive officer and founder of Amalgam Rx.
About Sonny Vu
Sonny Vu is a senior executive with extensive experience at the intersection of health, technology, and consumer. He pioneered connected glucose meters, mobile medical applications, wearable activity trackers, digitized medical labs, and next-generation 3D printing all before their mass market inflection points. Founder of Misfit, a wearables company acquired by Fossil Group (NASDAQ: FOSL) for $260 million, Vu was appointed Fossil’s president and chief technology officer, Connected Devices. Today, he serves as founder of Alibaster (deep tech investment fund) and chief executive officer at AREVO (3D printed carbon fiber). Vu led two of Indegogo’s most successful campaigns and previously founded Elemental Machines (digitizing the lab), AgaMatrix (biosensors for diabetes), and FireSpout (natural language processing). “Sonny Vu is a successful serial entrepreneur who knows how to rapidly scale companies. His deep history in med tech, machine learning, artificial intelligence, and consumer products makes him an ideal contributor to Amalgam Rx’s vision of the future,” said Ryan Sysko, chief executive officer and founder of Amalgam Rx.
About Amalgam Rx
Amalgam Rx is the leader in bringing providers, life sciences, and digital solutions together. For more than 15 years, our team has been reimagining care delivery and creating lasting change across the chronic care ecosystem. Working in partnership with many of the world’s leading life sciences companies, Amalgam Rx has built an innovative platform for rapidly developing and scaling digital solutions — delivered through a wide variety of business models. Our proven end-to-end methodology enables the entire life cycle from R&D to commercialization. Amalgam’s solutions have generated more than 5 billion RWE data points utilized by patients and providers on three continents. For more information on how Amalgam Rx’s regulated, clinically validated technologies bring patients and providers closer together, reduce costs for payers, and unlock sustained value for partners, visit amalgamrx.com.